IL139699A0 - Novel serpentine transmembrane antigens expressed in human cancers and uses thereof - Google Patents

Novel serpentine transmembrane antigens expressed in human cancers and uses thereof

Info

Publication number
IL139699A0
IL139699A0 IL13969999A IL13969999A IL139699A0 IL 139699 A0 IL139699 A0 IL 139699A0 IL 13969999 A IL13969999 A IL 13969999A IL 13969999 A IL13969999 A IL 13969999A IL 139699 A0 IL139699 A0 IL 139699A0
Authority
IL
Israel
Prior art keywords
strap
family
prostate
human
expressed
Prior art date
Application number
IL13969999A
Other languages
English (en)
Original Assignee
Urogenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urogenesys Inc filed Critical Urogenesys Inc
Publication of IL139699A0 publication Critical patent/IL139699A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
IL13969999A 1998-06-01 1999-06-01 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof IL139699A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8752098P 1998-06-01 1998-06-01
US9118398P 1998-06-30 1998-06-30
PCT/US1999/012157 WO1999062941A2 (en) 1998-06-01 1999-06-01 Serpentine transmembrane antigens expressed in human cancers and uses thereof

Publications (1)

Publication Number Publication Date
IL139699A0 true IL139699A0 (en) 2002-02-10

Family

ID=26777066

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13969999A IL139699A0 (en) 1998-06-01 1999-06-01 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
IL203524A IL203524A (en) 1998-06-01 2010-01-26 Isolated steap-1 protein, a preparation that includes it, a process for its preparation and use

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL203524A IL203524A (en) 1998-06-01 2010-01-26 Isolated steap-1 protein, a preparation that includes it, a process for its preparation and use

Country Status (13)

Country Link
US (10) US6329503B1 (enExample)
EP (2) EP2080802B1 (enExample)
JP (5) JP4855577B2 (enExample)
AT (1) ATE437947T1 (enExample)
AU (1) AU757698C (enExample)
CA (1) CA2328989C (enExample)
CY (1) CY1109509T1 (enExample)
DE (1) DE69941187D1 (enExample)
DK (1) DK1086223T3 (enExample)
ES (2) ES2629442T3 (enExample)
IL (2) IL139699A0 (enExample)
PT (1) PT1086223E (enExample)
WO (1) WO1999062941A2 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US20020187472A1 (en) * 2001-03-09 2002-12-12 Preeti Lal Steap-related protein
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20040141975A1 (en) * 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
EP2080802B1 (en) * 1998-06-01 2017-03-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040048798A1 (en) * 1999-06-01 2004-03-11 Raitano Arthur B. Nucleic acid and corresponding protein entitle 98P4B6 useful in treatment and detection of cancer
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2000071711A2 (en) * 1999-05-20 2000-11-30 Fahri Saatcioglu Differentially expressed genes in prostate cancer
EP1244705B1 (en) * 1999-12-06 2010-01-27 Agensys, Inc. Serpentine transmembrane antigens expressed in human prostate cancers and uses thereof
TWI373343B (en) * 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
US7189565B2 (en) 2001-03-23 2007-03-13 Fahri Saatcioglu Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US7611892B2 (en) 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
JP2004521602A (ja) * 2000-03-24 2004-07-22 ファハリ サッチオグリュ 前立腺特異的または精巣特異的な新規の核酸分子、ポリペプチド、ならびに診断法および治療法
CA2434490C (en) 2001-01-17 2014-06-03 Intreat Pty Limited Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
EP2287186B1 (en) * 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7494646B2 (en) * 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
AU2002360670A1 (en) * 2001-12-19 2003-07-09 Wilk Patent Development Corporation Method and related composition employing nanostructures
EP1487965A4 (en) 2002-02-25 2006-11-15 Mpex Pharmaceuticals Inc MINI COMPOSITIONS AND METHODS
EP2181595A1 (en) * 2002-08-16 2010-05-05 Yeda Research And Development Company Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
JP5840351B2 (ja) * 2002-09-06 2016-01-06 アジェンシス，インコーポレイテッド 癌の処置および検出において有用な９８ｐ４ｂ６と称される、核酸および対応タンパク質
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
CA2563735C (en) 2004-04-22 2020-07-14 Agensys, Inc. Antibodies and molecules derived therefrom that bind to steap-1 proteins
US8765164B2 (en) * 2005-10-21 2014-07-01 Kenneth W. Carpenter Poly(ester urea) polymers and methods of use
JP2009531324A (ja) 2006-03-20 2009-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
US20100036101A1 (en) * 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
EP2061814B1 (en) 2006-10-27 2012-06-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
CL2008002083A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
JP5624885B2 (ja) 2007-09-14 2014-11-12 バイオセプター・インターナショナル・リミテッド 細胞外体液中のプリン作動性（ｐ２ｘ）受容体
CA2737126C (en) 2007-09-14 2018-05-01 Biosceptre International Limited Novel p2x7 epitopes
CA2700410C (en) * 2007-10-03 2020-10-06 Cornell University Treatment of proliferative disorders using antibodies to psma
ES2643239T3 (es) 2008-01-31 2017-11-21 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
ES2610225T3 (es) 2008-07-04 2017-04-26 Biosceptre (Aust) Pty Ltd Péptidos y epítopos anti P2X7
WO2010096486A1 (en) 2009-02-17 2010-08-26 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
ES2557456T3 (es) 2009-08-20 2016-01-26 Biosceptre (Aust) Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
EP2506876B1 (en) 2009-12-02 2016-10-12 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
AU2010336032C1 (en) 2009-12-24 2016-04-21 Biosceptre International Limited Antibodies to non-functional oligomeric P2X7 receptors
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
NZ701208A (en) 2010-06-03 2016-05-27 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
CN106310245A (zh) 2010-09-10 2017-01-11 生物权威(澳大利亚)有限责任公司 陪伴动物治疗
WO2012057765A1 (en) 2010-10-28 2012-05-03 The Board Of Regents Of The University Of Texas System Recombinant anti-cd19 monoclonal antibodies
EP3536703B1 (en) * 2010-11-12 2021-05-26 The Trustees of the University of Pennsylvania Consensus prostate antigens, nucleic acid molecules encoding the same and uses thereof
AU2015261742B2 (en) * 2010-11-12 2017-10-26 Inovio Pharmaceuticals, Inc. Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
EP2675474B1 (en) 2011-02-15 2019-01-16 Vaxiion Therapeutics, LLC Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
US9566318B2 (en) 2011-07-01 2017-02-14 Biosceptre (Aust) Pty Ltd Combination therapy
US20130143237A1 (en) 2011-11-29 2013-06-06 Genentech, Inc. Compositions and methods for prostate cancer analysis
MY171561A (en) 2012-11-15 2019-10-18 Endocyte Inc Conjugates for treating diseases caused by psma expressing cells
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
KR101782623B1 (ko) 2013-07-10 2017-09-28 서울대학교산학협력단 복합 막횡단 단백질의 세포막외 펩타이드 항원 및 그의 용도
GEP20237479B (en) 2013-10-18 2023-03-27 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3069147A4 (en) 2013-11-14 2017-10-11 Endocyte, Inc. Compounds for positron emission tomography
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
EP3307780A1 (en) 2015-06-15 2018-04-18 Genentech, Inc. Antibodies and immunoconjugates
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
CN109152811A (zh) 2015-12-18 2019-01-04 阿吉尔瓦克斯公司 与xCT肽相关的组合物和方法
WO2018058001A1 (en) * 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
FI3548515T3 (fi) 2016-12-01 2026-03-04 Regeneron Pharma Radioleimattuja anti-PD-L1-vasta-aineita immuno-PET-kuvantamiseen
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
AU2018247767B2 (en) 2017-04-03 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to STEAP-1
JP2020518668A (ja) 2017-05-01 2020-06-25 アジルバックス インコーポレイテッド ｘＣＴ抗体に関連する組成物および方法
EP3635009B1 (en) 2017-06-07 2026-02-25 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
SG11202010217YA (en) 2018-04-17 2020-11-27 Endocyte Inc Methods of treating cancer
MA52626A (fr) 2018-05-17 2021-03-24 Regeneron Pharma Anticorps anti-cd63, conjugués et leurs utilisations
US11530274B2 (en) 2018-07-02 2022-12-20 Amgen Inc. Anti-STEAP1 antigen-binding protein
BR112021000914A2 (pt) * 2018-07-18 2021-04-13 Amgen Inc. Receptores quiméricos para steap1 e seus métodos de uso
US12473265B2 (en) 2019-05-20 2025-11-18 Endocyte, Inc. Methods for preparing PSMA conjugates

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5851764A (en) * 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
AU8116494A (en) 1993-11-12 1995-06-13 Kenichi Matsubara Gene signature
ATE318147T1 (de) * 1996-03-25 2006-03-15 Medarex Inc Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
US5859045A (en) * 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
ATE305140T1 (de) * 1996-07-15 2005-10-15 Mayo Foundation Verfahren zur detektion der hk2 polypeptide
US5824504A (en) 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
DE19641560A1 (de) * 1996-10-09 1998-04-16 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen einen Komplex aus humanem ACT und einer Serinprotease
WO1998016628A1 (en) 1996-10-15 1998-04-23 The Regents Of The University Of California Animal models of human prostate cancer progression
WO1998018489A1 (en) 1996-10-30 1998-05-07 The Uab Research Foundation Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
EP0972201B1 (en) 1997-02-25 2005-08-17 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
CN1195851C (zh) 1997-02-25 2005-04-06 科里克萨有限公司 用于前列腺癌免疫疗法的化合物及其用途
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2290783A1 (en) * 1997-05-23 1998-11-26 Biogen, Inc. Modulators of tissue regeneration
PT1000146E (pt) 1997-08-01 2006-10-31 Serono Genetics Inst Sa Ests 5' para proteinas secretadas sem especificidade tecidular
AU8555198A (en) 1997-08-01 1999-02-22 Genset 5' ests for secreted proteins expressed in prostate
JPH11164691A (ja) 1997-10-03 1999-06-22 Rikagaku Kenkyusho 胚盤胞ｃＤＮＡ
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6255049B1 (en) * 1998-02-27 2001-07-03 The Trustees Of Columbia University In The City Of New York Detection of metastatic cancer cells using PCTA-1
US20030064397A1 (en) 1998-05-22 2003-04-03 Incyte Genomics, Inc. Transmembrane protein differentially expressed in prostate and lung tumors
US6048970A (en) 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
EP2080802B1 (en) * 1998-06-01 2017-03-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
KR20010083111A (ko) 1998-07-14 2001-08-31 길리스 스티브 전립선암의 치료 및 진단을 위한 조성물 및 방법
JP2002532083A (ja) 1998-12-17 2002-10-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４７個のヒト分泌タンパク質
ES2223705T3 (es) * 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
AU5457000A (en) 1999-06-11 2001-01-02 Human Genome Sciences, Inc. 48 human secreted proteins
CA2382015A1 (en) 1999-08-17 2001-02-22 Incyte Genomics, Inc. Membrane associated proteins
GB2354821A (en) 1999-09-29 2001-04-04 Dine O Quick Threshold crossing counter
WO2001025272A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2391369A1 (en) 1999-11-12 2001-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1244705B1 (en) 1999-12-06 2010-01-27 Agensys, Inc. Serpentine transmembrane antigens expressed in human prostate cancers and uses thereof
EP1261708A2 (en) 2000-01-14 2002-12-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1572987A4 (en) 2000-02-03 2005-11-30 Nuvelo Inc NUCLEIC ACIDS AND POLYPEPTIDES
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
WO2001060860A2 (en) 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
JP2004521602A (ja) 2000-03-24 2004-07-22 ファハリ サッチオグリュ 前立腺特異的または精巣特異的な新規の核酸分子、ポリペプチド、ならびに診断法および治療法
JP2004504808A (ja) 2000-03-27 2004-02-19 コリクサ　コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP2004509612A (ja) 2000-06-05 2004-04-02 アバロン　ファーマシューティカルズ ガン遺伝子決定および特徴的な遺伝子群を用いた治療用スクリーニング
AU2001268259A1 (en) 2000-06-09 2001-12-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002010449A2 (en) 2000-07-28 2002-02-07 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
AU2001270118A1 (en) 2000-08-24 2002-03-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002215345A1 (en) 2000-10-13 2002-04-22 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
CA2429343A1 (en) 2000-11-17 2002-08-01 Hyseq, Inc. Nucleic acids and polypeptides
WO2002057303A2 (en) 2001-01-12 2002-07-25 Hybrigenics Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
EP1414845A4 (en) 2001-03-21 2009-07-08 Human Genome Sciences SEPARATE HUMAN PROTEINS
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US7494646B2 (en) * 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP2287186B1 (en) 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
EP1308459A3 (en) 2001-11-05 2003-07-09 Research Association for Biotechnology Full-length cDNA sequences
US6918525B2 (en) * 2003-05-23 2005-07-19 Worktools, Inc. Spring energized desktop stapler
CA2563735C (en) * 2004-04-22 2020-07-14 Agensys, Inc. Antibodies and molecules derived therefrom that bind to steap-1 proteins
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US7056186B1 (en) * 2005-04-06 2006-06-06 Weyenberg Karey M Cleavage-enhancing foundation garment

Also Published As

Publication number Publication date
JP5683414B2 (ja) 2015-03-11
JP2017079748A (ja) 2017-05-18
JP2009106284A (ja) 2009-05-21
US7928201B2 (en) 2011-04-19
ES2329851T3 (es) 2009-12-01
JP4871341B2 (ja) 2012-02-08
US8414898B2 (en) 2013-04-09
AU4326299A (en) 1999-12-20
CA2328989C (en) 2012-02-07
US7642054B2 (en) 2010-01-05
US20100190962A1 (en) 2010-07-29
CY1109509T1 (el) 2014-08-13
AU757698C (en) 2004-04-08
US6887975B2 (en) 2005-05-03
US20030055217A1 (en) 2003-03-20
PT1086223E (pt) 2009-11-03
AU757698B2 (en) 2003-03-06
US20070104720A1 (en) 2007-05-10
US7575749B2 (en) 2009-08-18
JP6371362B2 (ja) 2018-08-08
DK1086223T3 (da) 2009-11-30
ATE437947T1 (de) 2009-08-15
EP1086223A2 (en) 2001-03-28
US7053186B2 (en) 2006-05-30
US20050202454A1 (en) 2005-09-15
US20030045682A1 (en) 2003-03-06
ES2629442T3 (es) 2017-08-09
CA2328989A1 (en) 1999-12-09
US7968307B2 (en) 2011-06-28
US7611904B2 (en) 2009-11-03
US20110318371A1 (en) 2011-12-29
JP2002517184A (ja) 2002-06-18
WO1999062941A2 (en) 1999-12-09
US20050064445A1 (en) 2005-03-24
WO1999062941A9 (en) 2000-09-14
US20060147951A1 (en) 2006-07-06
US20100173297A1 (en) 2010-07-08
JP2012050434A (ja) 2012-03-15
JP2014239695A (ja) 2014-12-25
EP1086223B1 (en) 2009-07-29
JP4855577B2 (ja) 2012-01-18
WO1999062941A3 (en) 2000-04-06
EP2080802A2 (en) 2009-07-22
WO1999062941A8 (en) 2000-08-03
IL203524A (en) 2013-06-27
US7166714B2 (en) 2007-01-23
EP2080802B1 (en) 2017-03-29
US6329503B1 (en) 2001-12-11
DE69941187D1 (de) 2009-09-10
EP2080802A3 (en) 2009-08-05

Similar Documents

Publication Publication Date Title
IL139699A0 (en) Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
IL199275A0 (en) Serpentine transmembrane sntigens expressed in human prostate cancers and uses thereof
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
FI964766A0 (fi) Keuhkopintaproteiinin SP-C synteettiset peptidianalogit
AU2001254624A1 (en) Human coagulation factor vii variants
CA2092533A1 (en) Nucleotide sequences coding for a human protein with angiogenesis regulative properties
MX336118B (es) Expresion hibrida y en tandem de proteinas de neisseria.
RU2002124123A (ru) Модифицированный фактор viii
TR200100074T2 (tr) Nevrotrofik büyüme faktörü
FR2649982B1 (fr) Membrane biologique artificielle
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
DE60226896D1 (de) Herstellung von f(ab')2 fragmenten in saügetierzelle
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
PT1200476E (pt) Proteínas e anticorpos antitumorais, e suas utilizações
WO2001098355A3 (en) Cgi-69 compositions and methods of use
WO2000004157A3 (en) Cloning and characterisation of novel mammalian peptidases
Niemčić Dance and Gender/Sex in the Lastovo Carnival
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
ES8705466A1 (es) Un metodo para la preparacion del factor nkbs regulador del cancer humano.
WO2001082948A3 (en) Uses of tgap7 for the modulation of leucocyte activation
AU2001281943A1 (en) The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof
TR199900160T2 (xx) Immunoterapötik aktif maddeler olarak kullanışlı polipeptidler.
NO20000694L (no) Fremgangsmåte for fremstilling av kontrastmidler som i utstrakt grad er fri for bivirkninger

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
EXP Patent expired